Whether viruses or immunologic factors might cause or prevent human brain cancer is of interest. Statistically significant inverse associations of adult glioma with history of chickenpox and immunoglobulin G antibodies to varicella-zoster virus have been reported. The authors evaluate associations of immunoglobulin G antibodies to varicella-zoster virus and three other herpesviruses among 229 adults with glioma and 289 controls in the San Francisco Bay Area Adult Glioma Study (1997)(1998)(1999)(2000). Cases were less likely than controls to report a history of chickenpox (for self-reported cases vs. controls: the age-, gender-, and ethnicity-adjusted odds ratio ¼ 0.59, 95% confidence interval: 0.40, 0.86), and they also had lower levels of immunoglobulin G to varicella-zoster virus (for being in the highest quartile vs. the lowest quartile: the age-, gender-, and ethnicity-adjusted odds ratio ¼ 0.41, 95% confidence interval: 0.24, 0.70). The inverse association with anti-varicella-zoster virus immunoglobulin G was most marked for glioblastoma multiforme cases versus controls and was only somewhat attenuated by excluding subjects taking high-dose steroids and other medications. Cases and controls did not differ notably for positivity to three other herpesviruses, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus. Cohort studies may help to clarify the nature of the association between immunity to and/or clinical manifestations of varicella-zoster virus and glioblastoma.
Few risk factors for adult glioma have been established, and those that have, high-dose radiation exposures and a few genetic syndromes, are rare and account for a small proportion of cases (1, 2) . Immunologic responses and viral infections have long been thought to have potential to influence carcinogenesis (3, 4) ; a variety of spontaneous animal malignancies are related to viral infections, several human cancers (Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease) are associated with EpsteinBarr virus (a herpesvirus), and several other types of human cancers have been linked to other viruses. Epidemiologic evidence for a role of immunologic responses influencing cancer progression comes from two different lines of evidence (4) . Studies of the immune compromised (e.g., transplant or acquired immunodeficiency syndrome patients, persons with genetically determined immunodeficiency diseases) show an increase of certain cancers in affected individuals, while studies dating back to the 1950s have shown an inverse association of allergic diseases with a variety of cancers, although some studies have found no association or positive associations. One researcher summed up the evidence for immune surveillance's playing a role in carcinogenesis in this way: ''Overall, the evidence on cancer and immune impairment suggests that immunosurveillance in humans operates primarily against malignancies that are either viral in origin or possibly highly antigenic in nature. In this respect there is striking similarity between the human and animal evidence'' (4, p. 541).
Regarding gliomas, several studies have attempted to clarify an association between brain tumors and infections with the polyoma viruses simian virus 40, BK virus, and/or JC virus (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Although results have been mixed because of small sample sizes, retrospective assessment, and differences in analytical models, a recent small case-control study in which specimens were obtained from 1 to 22 years prior to brain tumor onset reported small nonsignificant increased risk associated with antibodies to JC virus (odds ratio (OR) ¼ 1.46, 95 percent confidence interval (CI): 0.61, 3.5), decreased risk with antibodies to BK virus (OR ¼ 0.66, 95 percent CI: 0.22, 1.95), and no association with antibodies to simian virus 40 (OR ¼ 1.00, 95 percent CI: 0.30, 3.32) (5) . Other studies have examined associations of brain tumors with herpesviruses or diseases such as chickenpox and shingles caused by the herpesvirus, varicella-zoster virus. Bithell et al. (15) found an increased risk of brain tumors among children of mothers who had chickenpox during the index pregnancy. Some of us previously reported that adults with glioma were less likely than controls to have a history of chickenpox and shingles and that cases with glioblastoma were less likely than controls to have immunoglobulin G for varicella-zoster virus (16) (17) (18) .
In addition to studies of viruses or immunity to viruses, several large case-control studies and a cohort study have demonstrated an inverse association of adult glioma with allergic diseases (19) (20) (21) (22) , and a case-control study has shown an inverse association of immunoglobulin E levels with glioma (23) . While the immunosuppressive effects noted among glioma patients may be the result of tumorsecreted factors or disease activity (24) , the extent to which such immunosuppression precedes the clinically recognized tumor is unknown, as patients are seldom identified early in the course of gliomagenesis.
In the present study, we examine whether history of varicella-zoster virus infections or immunity to varicellazoster virus or to other herpesviruses is associated with glioma in a new series of adults with glioma and controls in the San Francisco Bay Area of California.
MATERIALS AND METHODS

Study subjects, interviews, and specimen collection
The University of California, San Francisco, Institutional Review Board approved the methods for subject involvement, and all subjects provided signed consent for participating in this study. Details of subject recruitment, interview, and specimen collection have been described elsewhere (20, 23, 25) . Eligible cases, ascertained through the Northern California Cancer Center's rapid case ascertainment system, included all adults (aged 20 years or older) newly diagnosed with glioma (International Classification of Diseases for Oncology morphology codes 9380-9481) who resided in the six-county San Francisco Bay Area between May 1997 and August 1999. Controls were selected through random digit dialing and frequency matched to cases by age, ethnicity, and gender. Pathology material was reviewed and classified by a single neuropathologist (K. A.). In-person interviews sought detailed medical histories prior to brain tumor diagnosis for cases or interview for controls, including history of chickenpox or shingles. Proxies provided interview data for cases who were deceased or too ill to participate. Blood and sera were collected either at the time of interview or as soon after as possible. At the time of blood draw, participants were asked about currently used medications and recent chemotherapy and radiation therapy because of the possibility that these factors might influence serologic results. For analytical purposes, the current medications reported by subjects on the blood draw questionnaire were classified as follows: 1) chemotherapeutic; 2) DNA/RNA polymerase poison (e.g., antiretrovirals); 3) antibiotic or antiviral; 4) nonsteroidal antiinflammatory and analgesic; 5) antihistamine, antileukotriene, or other allergy medication; 6) high-dose steroids (e.g., dexamethasone); and 7) other medications.
Varicella-zoster virus-, cytomegalovirus-, Epstein-Barr virus-, and herpes simplex virus-specific antibody assays
Anti-varicella-zoster virus, cytomegalovirus, and EpsteinBarr virus viral capsid antigen serum immunoglobulin G was measured using commercial enzyme immunoassay kits (Diamedix Corporation, Miami, Florida). Similar methodology was used for measuring immunoglobulin G antibodies to herpes simplex virus types 1 and 2 (DiaSorin, Inc., Stillwater, Minnesota). Assays were performed according to the manufacturers' instructions except for varicella-zoster virus, which was modified in order to provide quantitative measurements. Serial dilutions of the World Health Organization varicella-zoster virus immunoglobulin G standard were included in each run and used to generate a linear regression curve correlating the absorbance reading of the reaction wells with the antibody titer. The regression curve was linear between 1 and 10 mIU/ml. Test sera varicella-zoster virus antibody titers were determined by interpolating their absorbance readings on the standard curve. Sera whose absorbance readings exceeded the upper limit of the linear portion of the regression curve were retested at higher dilutions, which were factored into the final titer calculations. Quantitative assessments were made to enhance precision of case-control comparisons of anti-varicella-zoster virus titers.
Statistical methods
Proportions of people positive for immunoglobulin G to the four herpesviruses and means and standard errors of log levels of anti-varicella-zoster virus immunoglobulin G overall and by gender and ethnicity were calculated separately for cases and controls with the FREQ and MEANS procedures from the SAS Institute, Inc. (Cary, North Carolina) (26) ; additionally, quartiles of anti-varicella-zoster virus immunoglobulin G were computed with the SAS procedure UNIVARIATE using values for controls. Average ages of cases and controls, positive and negative for antibodies to the four herpesviruses, and quartiles of antivaricella-zoster virus immunoglobulin G were compared with one-way analysis of variance using the SAS procedure NPAR1WAY. Odds ratios were used to compare cases and controls for history of chickenpox or shingles and for continuous levels and quartiles of anti-varicella-zoster virus immunoglobulin G, as well as categories of positive versus negative values of immunoglobulin G to Epstein-Barr virus, herpes simplex virus, and cytomegalovirus. Odds ratios adjusted for age, gender, and ethnicity (White, non-White) were estimated with logistic regression using the SAS procedure LOGISTIC (26) . In addition, age-, gender-, and ethnicity-adjusted models were calculated to include immunoglobulin G to all viruses and socioeconomic status (categorized as college or less than college educated). We also estimated models separately for cases and controls aged 55 years or less at diagnosis for cases or interview for controls and older than age 55 years. Separately in cases and controls, we used general linear models (SAS procedure GLM) adjusting for age, gender, and ethnicity to examine mean log anti-varicella-zoster virus immunoglobulin G levels in relation to reported history of chickenpox, shingles, and medication use as reported on the blood draw questionnaire. For cases only, the mean log anti-varicella-zoster virus immunoglobulin G levels were also compared by extent of brain tumor surgery, radiation therapy, and first-course chemotherapy as reported by the SEER Cancer Statistics Review, 1973-1999. We used logistic regression for similar comparisons of the odds of positivity of immunoglobulin G to Epstein-Barr virus, cytomegalovirus, or herpes simplex virus in relation to medications and brain tumor therapy. We then estimated logistic models of case-control status with immunoglobulin G to herpesviruses after removing subjects who were taking medications or who had had treatments that were shown to influence immunoglobulin G results. All statistical tests were two sided.
RESULTS
Details of participation rates for eligible cases and controls and for specimen collection are presented elsewhere (20, 25, 27) . Briefly, 79 percent (401/509) of eligible cases or their proxies and 74 percent (402/541) of eligible controls completed full interviews. Serologic samples were available for 229 of 401 cases (57 percent) and for 289 of 402 controls (72 percent) with interview data (table 1). The younger average age and lower percentage of glioblastoma among cases with serologic studies (table 1) are due to the poorer survival among older subjects and among subjects with glioblastoma. In addition, younger controls were more likely than older controls to refuse blood draw. Blood was obtained on average 4.5 months (median of 3.7 months) after the case diagnosis.
Univariate comparisons of immunoglobulin G to herpesviruses by case-control status, ethnicity, gender, and age Similar percentages of cases and controls were positive for antibodies to the four herpesviruses (table 2) . However, a higher percentage of cases than controls had anti-varicellazoster virus immunoglobulin G in the lower versus upper quartiles, and this was especially marked for glioblastoma cases versus controls (table 2) . Similarly, the mean log antivaricella-zoster virus immunoglobulin G levels were lower for cases than controls and were lowest for glioblastoma cases (table 2) .
Among both controls and cases, a higher percentage of non-Whites than Whites was positive for antibodies to cytomegalovirus, but similar percentages of non-Whites and Whites were positive for antibodies to herpes simplex virus, Epstein-Barr virus, and varicella-zoster virus (table 3) . Among controls, average anti-varicella-zoster virus immunoglobulin G log levels were lower among non-Whites than Whites, and a lower percentage of non-Whites than Whites had anti-varicella-zoster virus immunoglobulin G levels in the upper quartiles (table 3) . However, among cases, log levels of anti-varicella-zoster virus immunoglobulin G were somewhat higher in non-Whites than Whites, and the quartile distributions for anti-varicella-zoster virus immunoglobulin G were similar in Whites and non-Whites (table 3) . Among controls, a higher percentage of females than males was positive for immunoglobulin G antibodies to herpes simplex virus, Epstein-Barr virus, and varicellazoster virus, but similar proportions of women and men were positive for anti-cytomegalovirus immunoglobulin G (table 3) . Examination of quartiles and log levels of antivaricella-zoster virus immunoglobulin G suggested that female controls had somewhat higher levels of anti-varicellazoster virus antibodies than did male controls. Among cases, gender differences similar to those observed in controls were apparent for antibodies to herpes simplex virus and varicella-zoster virus, and a higher proportion of female than male cases was positive for antibodies to cytomegalovirus (table 3) . There was only a small difference in percentages of female and male cases positive for antibodies to Epstein-Barr virus.
Regarding age, both cases and controls who were positive for antibodies to herpes simplex virus and cytomegalovirus were significantly older, on average, than those who were negative (table 4) . In contrast, the average ages of cases and controls positive and negative for immunoglobulin G antibodies to Epstein-Barr virus and varicella-zoster virus were very similar. However, for cases, the average ages of those in the lower quartiles of immunoglobulin G to varicella-zoster virus were older than those in the highest quartiles (p ¼ 0.003) (table 4), with a noticeable trend of decreasing average age with increasing quartile of anti-varicella-zoster virus immunoglobulin G. This trend was not apparent in controls.
Multivariate comparisons
With adjustments for age, gender, and ethnicity, cases were only somewhat more likely than controls to be positive for immunoglobulin G antibodies to herpes simplex virus and cytomegalovirus and somewhat less likely to be positive for antibodies to Epstein-Barr virus, but the results were not statistically significant (table 5, model A). Cases were significantly less likely than controls to have anti-varicellazoster virus immunoglobulin G in the fourth versus the first quartile, and the odds ratio for glioma was significantly reduced for increasing log levels of anti-varicella-zoster virus immunoglobulin G (table 5, model A). These results were most marked and only achieved statistical significance when comparing glioblastoma cases with controls (table 5, model A). The magnitude and significance of quartile comparisons were essentially unchanged by including data on antibodies to the other three herpesviruses in the model (table 5, model B) . Although all models were rerun to adjust for a socioeconomic indicator (subject college educated vs. not college educated), the results are not shown, as they were almost identical to those shown in table 5.
Multivariate comparisons corresponding to those in table 5, model B, stratified by age showed that the case-control odds ratio for the fourth versus the first quartile of antivaricella-zoster virus immunoglobulin G deviated more from the null for older-versus younger-onset cases; for For cases, we examined the influence of chemotherapy or radiation therapy categorized as first course of treatment and extent of surgery (biopsy only vs. resection) on antibodies to the herpesviruses. Those who had only biopsy had significantly lower mean log anti-varicella-zoster virus immunoglobulin G levels (results not shown). For controls, the mean anti-varicella-zoster virus immunoglobulin G levels were not significantly associated with the current medications used as reported on the blood draw questionnaire (results not shown). However, the 77 cases who reported taking decadron or dexamethasone had lower and the 13 cases who reported taking antibiotics had higher anti-varicella-zoster History of chickenpox and shingles in cases and controls and association of clinical history with antivaricella-zoster virus immunoglobulin G Cases were significantly less likely than controls to report a history of chickenpox, regardless if the history among cases was self-reported or proxy reported (table 6). The odds for reporting a history of shingles were also less than one, but they were not statistically significant (table 6) . Moreover, as expected, proxies were much more likely to report unknown histories of chickenpox or shingles for the cases. Among selfreported cases versus controls, with adjustment for age, gender, and ethnicity, the odds for history of chickenpox were 0.53 (95 percent CI: 0.34, 0.84) for glioblastoma cases and 0.61 (95 percent CI: 0.37, 1.02) for other histologies (these histology-specific results are not shown in table 6). Both cases and controls reporting a history of chickenpox had significantly higher average levels of anti-varicella-zoster virus immunoglobulin G than those reporting no history (table 7) . Controls who reported having chickenpox during childhood (before the age of 13 years) had somewhat lower levels of immunoglobulin G for varicella-zoster virus than those reporting chickenpox after the age of 12 years. In contrast, cases who reported chickenpox after childhood had somewhat lower levels of immunoglobulin G for varicellazoster virus than those who reported the disease occurring during childhood; however, neither of these differences approached statistical significance (results not shown). The average levels of immunoglobulin G to varicella-zoster virus were also higher among both cases and controls reporting a history of shingles compared with those who had no history, but the results were not significant (table 7) .
DISCUSSION
These results suggest that glioma cases (particularly those with glioblastoma) have significantly lower levels of antivaricella-zoster virus immunoglobulin G than do controls and that they also are less likely than controls to report a history of chickenpox. The high proportions of cases and controls positive for anti-varicella-zoster virus antibodies are not unexpected, as over 99 percent of adults aged 40 years or more were positive for immunoglobulin G to varicella-zoster virus among participants in the Third National Health and y Continuous log 10 -transformed levels of immunoglobulin G to varicella-zoster virus. z Quartile cutoffs based on levels of immunoglobulin G to varicella-zoster virus in controls. § Model B: one model including antibodies to all four viruses. { Excluding cases who had biopsy only and subjects who reported taking decadron, dexamethasone, or antibiotics at the time of blood draw, corresponding odds ratios for the 4th versus the 1st quartile of anti-varicella-zoster virus antibodies were 0.49 (95% confidence interval: 0.24, 0.97) for all remaining cases (n ¼ 128), 0.40 (95% confidence interval: 0.14, 1.10) for glioblastoma cases (n ¼ 47), and 0.56 (95% confidence interval: 0.24, 1.33) for other glioma cases (n ¼ 81) versus controls (n ¼ 264).
Nutrition Examination Survey (NHANES III) from 1988 to 1994 (28) . For younger individuals in this survey, seropositivity was related to ethnicity, marital status, and reproductive history, with Whites, married men, and parous women being more likely to be seropositive. Adjustment for age, gender, ethnicity, education, or positivity of immunoglobulin G to three other herpesviruses did not materially alter the finding that cases were more likely than controls to have antivaricella-zoster virus antibody levels in the lower quartile. The odds ratios were statistically significant overall for glioblastoma cases versus controls, but not for other glioma histologies versus controls. The cases and controls in this report were ascertained in later years from the same geographic area as the subjects included in the earlier reports (16) (17) (18) . It is important to emphasize that none of the cases in this report were included in the previous report and, thus, represent an independent series of subjects. Since the results from this new series are similar to those of our previous reports (16) (17) (18) , there is added support to the conclusion that the observed associations between glioma and history of chickenpox and anti-varicella-zoster virus antibodies are unlikely to be due to a chance observation. However, it remains to be determined whether the associations are causal.
A primary issue to understand is whether the lowered anti-varicella-zoster virus immunoglobulin G levels precede or result from glioma or related treatments. Although the results for anti-varicella-zoster virus immunoglobulin G were somewhat attenuated when we excluded subjects from analysis who were taking medications that might reduce anti-varicella-zoster virus immunoglobulin G levels, the inverse odds ratio for the fourth versus the first quartile of anti-varicella-zoster virus immunoglobulin G for cases of any histology versus controls remained statistically significant. Although the corresponding odds ratio for glioblastoma cases versus controls did not achieve statistical significance, the magnitude remained substantially below the null (OR ¼ 0.40, 95 percent CI: 0.14, 1.10), and the markedly reduced sample size for this comparison could account for the lack of statistical significance.
There also may be potential biases resulting from obtaining blood from a smaller percentage of cases than controls; the main reason for the difference in percentages of cases and controls providing blood is that some cases die before we can contact them about the study. If immunoglobulin G positivity or levels are unrelated to survival, there should be no systematic bias from differential participation in blood draw. If higher immunoglobulin G levels correlated with improved survival, higher levels would be found among cases in the serology set than in overall cases and, thus, the bias would be conservative. It seems unlikely that lower immunoglobulin G levels would be correlated with improved survival but, in this event, the odds ratios obtained would be overly low.
There is the potential that recall issues might explain some of the inverse association observed with history of chickenpox and glioma, since glioma cases might have poorer memory than controls have. There also is the potential that aspects of the disease or treatment might specifically diminish immunoglobulin G to varicella-zoster virus, but it is difficult to understand how such an effect would be limited to varicella-zoster virus and not influence positivity of immunoglobulin G to other herpesviruses. A well-designed cohort study with adequate numbers of glioma cases with welldefined histology would be needed to further resolve this issue.
If the inverse associations with chickenpox and immunoglobulin G to varicella-zoster virus are real and not due to artifacts of recall or effects of the disease, what are possible mechanisms for the association? We and others have discussed the previous literature on infections or immune response to infections or allergens and brain cancer risk (17, (20) (21) (22) (23) . Options include that infections or immune response to infections or allergens may decrease the chance of cancer development or may kill existing cancer cells; alternatively, infections may be less likely to arise in individuals who are more susceptible to cancer or who are developing cancer, or those who are more susceptible to cancer or who have developed cancer may show lower levels of immunity to infection. In addition, as we previously speculated, if a virus or viruses with some cross-reactivity to varicella-zoster virus influence glioma development, individuals with stronger immunity to varicella-zoster virus might be less susceptible to glioma. Alternatively, nascent tumor cells regardless of etiology might express antigens with crossreactivity to varicella-zoster virus antigens, and those with immunoglobulin G antibodies to these antigens might be more able to eliminate the nascent tumor cells or might improve cell-mediated immunity. Of interest in this regard are two recent studies (29, 30) suggesting that reexposure to varicella (chickenpox) through contacts with children boosted anti-varicella-zoster virus immunity and thereby lowered the risk of adult zoster (shingles). Another possibility is that latent varicella-zoster virus infection itself in some individuals might afford some protection against glioblastoma formation; perhaps premalignant or malignant conversion of cells might induce a cytolytic reaction among infected cells.
We did not ask about history of chickenpox vaccination and do not know how such vaccination would affect glioma risk. The varicella vaccine virus has the ability to establish latency and to reactivate, causing herpes zoster (shingles). Thus, it is conceivable that it might also reactivate asymptomatically and stimulate the same sort of central nervous system immunosurveillance as suggested here for naturally obtained varicella-zoster virus, but this is speculation. In addition, booster varicella-zoster virus immunization is under consideration, which would substitute the reexposures to wild-type virus in unvaccinated communities.
To conclude, cases were less likely than controls to report a history of chickenpox, and they also have lower levels of immunoglobulin G to varicella-zoster virus. Exclusion of subjects taking high-dose steroids and other medications somewhat attenuated but did not completely remove the negative association, which remained statistically significant in comparisons of all remaining cases with controls. As in the previous report (18) , no significant differences were noted between cases and controls for positivity to three other herpesviruses, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus. Since these results support the possibility of an inverse association between immunity to and/or clinical manifestations of varicella-zoster virus and glioblastoma and since few leads are available for understanding the etiology of this disease, we recommend that cohort studies be conducted to help to clarify the nature of the association.
